Sionna Therapeutics (SION) | Financial Analysis & Statements
Sionna Therapeutics Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-23.6M
Net Income
-20.4M
EPS (Diluted)
$-0.46
Balance Sheet Metrics
Total Assets
326.0M
Total Liabilities
19.1M
Shareholders Equity
306.8M
Debt to Equity
0.06
Cash Flow Metrics
Operating Cash Flow
-17.2M
Free Cash Flow
-16.8M
Revenue & Profitability Trend
Sionna Therapeutics Income Statement From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - |
| Gross Profit | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | ||||
| Research & Development | 60.3M | 57.3M | 40.6M | 34.6M |
| Selling, General & Administrative | 28.7M | 13.3M | 9.7M | 6.8M |
| Other Operating Expenses | - | - | - | - |
| Total Operating Expenses | 89.0M | 70.6M | 50.3M | 41.4M |
| Operating Income | -89.0M | -70.6M | -50.3M | -41.4M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | ||||
| Interest Income | 13.3M | 8.2M | 2.8M | 1.1M |
| Interest Expense | - | - | - | - |
| Other Non-Operating Income | 419.0K | 698.0K | 301.0K | - |
| Pre-tax Income | -75.3M | -61.7M | -47.3M | -40.2M |
| Income Tax | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -75.3M | -61.7M | -47.3M | -40.2M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | ||||
| EBITDA | -88.3M | -69.9M | -49.8M | -41.2M |
| EPS (Basic) | - | $-1.45 | $-12.25 | $-2.32 |
| EPS (Diluted) | - | $-1.45 | $-12.25 | $-2.32 |
| Basic Shares Outstanding | - | 42444742 | 3858859 | 17332468 |
| Diluted Shares Outstanding | - | 42444742 | 3858859 | 17332468 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Sionna Therapeutics Balance Sheet From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Assets | ||||
| Current Assets | ||||
| Cash & Equivalents | 58.5M | 37.8M | 38.5M | 54.8M |
| Short-term Investments | 177.4M | 109.8M | 0 | 27.8M |
| Accounts Receivable | - | - | - | - |
| Inventory | - | - | - | - |
| Other Current Assets | 5.5M | 3.5M | 686.0K | 1.2M |
| Total Current Assets | 241.4M | 151.0M | 39.2M | 83.8M |
| Non-Current Assets | ||||
| Property, Plant & Equipment | 8.5M | 9.3M | 10.0M | 617.0K |
| Goodwill | - | - | - | - |
| Intangible Assets | - | - | - | - |
| Long-term Investments | - | - | - | - |
| Other Non-Current Assets | 963.0K | 4.0M | 1.0M | 962.0K |
| Total Non-Current Assets | 84.5M | 34.8M | 12.7M | 3.5M |
| Total Assets | 326.0M | 185.8M | 51.9M | 87.4M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | 769.0K | 1.2M | 719.0K | 557.0K |
| Short-term Debt | 1.3M | 1.1M | 728.0K | - |
| Current Portion of Long-term Debt | - | - | - | - |
| Other Current Liabilities | 6.0K | - | - | - |
| Total Current Liabilities | 11.7M | 10.4M | 8.0M | 8.3M |
| Non-Current Liabilities | ||||
| Long-term Debt | 7.4M | 8.7M | 9.7M | 0 |
| Deferred Tax Liabilities | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - |
| Total Non-Current Liabilities | 7.4M | 339.0M | 9.7M | 0 |
| Total Liabilities | 19.1M | 349.5M | 17.8M | 8.3M |
| Equity | ||||
| Common Stock | 45.0K | 5.0K | 2.0K | 2.0K |
| Retained Earnings | -256.4M | -181.1M | -119.4M | -72.1M |
| Treasury Stock | - | - | - | - |
| Other Equity | - | - | - | - |
| Total Shareholders Equity | 306.8M | -163.7M | 34.2M | 79.1M |
| Key Metrics | ||||
| Total Debt | 8.7M | 9.7M | 10.5M | 0 |
| Working Capital | 229.7M | 140.6M | 31.2M | 75.6M |
Balance Sheet Composition
Sionna Therapeutics Cash Flow Statement From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | -75.3M | -61.7M | -47.3M | -40.2M |
| Depreciation & Amortization | 647.0K | 668.0K | 583.0K | 122.0K |
| Stock-Based Compensation | 12.1M | 3.7M | 2.3M | 1.7M |
| Working Capital Changes | -2.5M | -1.4M | -10.0K | -1.5M |
| Operating Cash Flow | -63.1M | -48.1M | -42.2M | -39.9M |
| Investing Activities | ||||
| Capital Expenditures | -377.0K | -27.0K | -1.1M | -1.9M |
| Acquisitions | - | - | - | - |
| Investment Purchases | -325.0M | -182.8M | -23.5M | -40.4M |
| Investment Sales | 206.7M | 56.0M | 52.0M | 13.0M |
| Investing Cash Flow | -118.7M | -126.9M | 27.4M | -29.3M |
| Financing Activities | ||||
| Share Repurchases | - | - | - | - |
| Dividends Paid | - | - | - | - |
| Debt Issuance | - | - | - | - |
| Debt Repayment | - | - | - | - |
| Financing Cash Flow | 202.1M | 178.8M | 0 | 110.8M |
| Free Cash Flow | -66.7M | -52.8M | -44.8M | -37.9M |
| Net Change in Cash | 20.2M | 3.8M | -14.9M | 41.6M |
Cash Flow Trend
Sionna Therapeutics Key Financial Ratios
Valuation Ratios
Forward P/E
-16.19
Price to Book
6.09
PEG Ratio
-16.19
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-31.79%
Return on Assets
-21.74%
Financial Health
Current Ratio
20.61
Debt to Equity
2.83
Per Share Data
EPS (TTM)
$-1.88
Book Value per Share
$6.86
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| SION | 1.7B | - | 6.09 | -31.79% | 0.00% | 2.83 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






